poisar

Stocks · News reference

Oppenheimer Raises Price Target on Tarsus Pharmaceuticals to $103

Oppenheimer has increased its price target for Tarsus Pharmaceuticals from $100 to $103 while maintaining an Outperform rating.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TARS
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

    Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.

    HRMYTAKTGTXTARS